千金药业2024年营业收入降4.4%，净利润降28%

财中社2025-04-28

4月28日，千金药业(600479)公布2024年年报，公司营业收入为36.3亿元，同比下降4.4%；归母净利润为2.31亿元，同比下降28.0%；扣非归母净利润为2.19亿元，同比下降27.9%；经营现金流净额为3.99亿元，同比下降10.0%；EPS(全面摊薄)为0.5442元。其中第四季度，公司营业收入为9.15亿元，同比下降10.2%；归母净利润为6268万元，同比下降49.2%；扣非归母...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530242072?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-28 17:20","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530242072","market":"sh","top_or_hot":-1,"title":"千金药业2024年营业收入降4.4%，净利润降28%","media":"财中社","content":"<div>\n<p>4月28日，千金药业(600479)公布2024年年报，公司营业收入为36.3亿元，同比下降4.4%；归母净利润为2.31亿元，同比下降28.0%；扣非归母净利润为2.19亿元，同比下降27.9%；经营现金流净额为3.99亿元，同比下降10.0%；EPS(全面摊薄)为0.5442元。其中第四季度，公司营业收入为9.15亿元，同比下降10.2%；归母净利润为6268万元，同比下降49.2%；扣非归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817221697484377&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>千金药业2024年营业收入降4.4%，净利润降28%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n千金药业2024年营业收入降4.4%，净利润降28%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-28 17:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817221697484377&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月28日，千金药业(600479)公布2024年年报，公司营业收入为36.3亿元，同比下降4.4%；归母净利润为2.31亿元，同比下降28.0%；扣非归母净利润为2.19亿元，同比下降27.9%；经营现金流净额为3.99亿元，同比下降10.0%；EPS(全面摊薄)为0.5442元。其中第四季度，公司营业收入为9.15亿元，同比下降10.2%；归母净利润为6268万元，同比下降49.2%；扣非归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817221697484377&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600479","symbol_name":"千金药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817221697484377&s=b","article_id":"2530242072","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042817221697484377&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530242072","pubTimestamp":1745832054,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公告中提到，公司在2024年度面临医药行业整体增长乏力的挑战，营业收入较去年略有下降，主要是由于公司主动收缩低毛利药品批发业务所致，但核心工业企业收入保持稳定增长。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"600479":"千金药业"},"translate_title":"Qianjin Pharmaceutical's operating income will drop by 4.4% in 2024, and its net profit will drop by 28%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600479":1},"content_text":"4月28日，千金药业(600479)公布2024年年报，公司营业收入为36.3亿元，同比下降4.4%；归母净利润为2.31亿元，同比下降28.0%；扣非归母净利润为2.19亿元，同比下降27.9%；经营现金流净额为3.99亿元，同比下降10.0%；EPS(全面摊薄)为0.5442元。其中第四季度，公司营业收入为9.15亿元，同比下降10.2%；归母净利润为6268万元，同比下降49.2%；扣非归母净利润为5686万元，同比下降50.5%；EPS为0.1478元。截至四季度末，公司总资产45.56亿元，较上年度末下降2.6%；归母净资产为24.62亿元，较上年度末增长3.0%。公告中提到，公司在2024年度面临医药行业整体增长乏力的挑战，营业收入较去年略有下降，主要是由于公司主动收缩低毛利药品批发业务所致，但核心工业企业收入保持稳定增长。管理层表示，净利润下降主要是由于研发费用增加及原药材价格上涨导致的成本上升。在战略执行方面，公司将2024年定为研发投入最高的一年，积极推进中药注册改革和化药集采，推出多个新产品，并在数字化转型上取得显著进展。此外，公司通过优化管理和人才战略，提升了内部组织的效率和市场竞争力，确保在行业变动中保持核心竞争力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530242072","isCrawlerRequest":true}